October 1, 2020 — According to our Q3 2020 survey of biotech and pharma thought leaders, over 90% experienced disruptions to trials in 2020. Respondents provided key insights into how this has shifted the paradigm for clinical, translational, and biomarker operations.
October 1, 2020 — In the months since March 2020, the biotech community has rallied to identify how our unique perspectives and skills can help with the COVID-19 pandemic. The computational biologists at QuartzBio are no different. QuartzBio’s Renee Deehan discusses how using existing published data to build a disease model can answer questions and […]
September 24, 2020 — The COVID-19 pandemic has forced clinical trial stakeholders to rethink the paradigm as sponsors adapt to site restrictions, remote monitoring, and updated regulatory guidance. This is especially true in precision medicine programs, which have developed global footprints in order to reach targeted patient populations and rely on specialty labs running complex […]
September 21, 2020 — What does precision medicine actually mean and how can AI and ML impact it? QuartzBio’s Renee Deehan and panelists explore AI and ML’s impact on precision medicine and what the industry needs to do to prepare for it, tackle challenges as they evolve and develop appropriate solutions. Learn More
August 27, 2020 — Machine learning and model-based drug discovery is rapidly becoming the norm. Computational biology is now integrating ‘wet’ in vitro/in vivo and ‘dry’ in silico biology accelerating and saving time and resources, at least in the early stages of drug discovery. This MassBio panel discussion explored the new world of digital biology […]
August 13, 2020 — Cell therapy clinical trials typically generate a significant quantity and diversity of biologic data intended to characterize disease and patient biology, as well as data intended to demonstrate evidence of therapeutic mechanisms. QuartzBio’s Cliff Culver et al., explores the benefits of capturing and integrating molecular biomarker data within clinical trials to […]
July 27, 2020 — QuartzBio’s Tobias Guennel, PhD, presented the following poster, “A Genetic Enrichment Strategy for Delay of Onset of Alzheimer’s Disease Clinical Trials,” at AAIC 2020. Download the poster
July 16, 2020 — Computational approaches using COVID-19 data can be invaluable in quickly generating insights for drug repurposing, target pathway selection, and many other challenges. In this webinar, QuartzBio’s Renee Deehan will discuss how teams are combining deep biological knowledge with computational and machine learning approaches. The global pandemic caused by SARS-CoV-2 has resulted […]
June 8, 2020 — As the QuartzBio team’s efforts have progressed with the selection and integration of SARS-CoV-2 / COVID-19 data sets, I am pleased to share our first public update on analysis. This work builds on an evaluation of IFN-α2b treatment, and supports the rationale that interferons are upregulated as part of the antiviral […]
May 20, 2020 — With new information around SARS-CoV-2 and COVID-19 surfacing on an almost daily basis, we are consistently reminded of the complexity and relatively unknown mechanisms behind why this disease presents with such a varying degree of severity. The impacts of COVID-19 infection on pediatric patients have been of particular concern in recent […]
